Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab
ABSTRACT Aims In March 2024, the American Society of Clinical Oncology recommended the combination of tremelimumab plus durvalumab as a treatment for advanced hepatocellular carcinoma (HCC). Although safety data for first‐line treatments are available, information on adverse events related to late‐l...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | JGH Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jgh3.70163 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850145072094380032 |
|---|---|
| author | Naohiro Watanabe Takashi Kobayashi Michihiro Iwaki Asako Nogami Naohiro Wada Ayako Shimizu Tomoya Komori Hirofumi Koike Yukiko Sahashi Atsushi Nakajima Masato Yoneda |
| author_facet | Naohiro Watanabe Takashi Kobayashi Michihiro Iwaki Asako Nogami Naohiro Wada Ayako Shimizu Tomoya Komori Hirofumi Koike Yukiko Sahashi Atsushi Nakajima Masato Yoneda |
| author_sort | Naohiro Watanabe |
| collection | DOAJ |
| description | ABSTRACT Aims In March 2024, the American Society of Clinical Oncology recommended the combination of tremelimumab plus durvalumab as a treatment for advanced hepatocellular carcinoma (HCC). Although safety data for first‐line treatments are available, information on adverse events related to late‐line treatments is limited. This study aimed to identify risk factors for adverse events in patients who received this combination. Methods and Results We conducted a retrospective cohort study from March 2023 to January 2025 at Yokohama City University Hospital, involving 24 patients aged 18 years or older with unresectable HCC. All 24 patients experienced at least one adverse event during treatment. Of these, the incidence of treatment‐related adverse events leading to treatment discontinuation after tremelimumab plus durvalumab therapy was 50.0% (12/24). In the discontinuation group, prior atezolizumab plus bevacizumab therapy (66.7% vs. 16.7%, p = 0.036) was more frequent than in the continuation group. Conclusion In patients with unresectable HCC who received tremelimumab plus durvalumab, the risk of treatment‐related adverse events was associated with prior atezolizumab plus bevacizumab therapy. These factors may increase the likelihood of developing treatment‐related adverse events. |
| format | Article |
| id | doaj-art-b4aac87fdc5a43f699f86c9766c810d4 |
| institution | OA Journals |
| issn | 2397-9070 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | JGH Open |
| spelling | doaj-art-b4aac87fdc5a43f699f86c9766c810d42025-08-20T02:28:11ZengWileyJGH Open2397-90702025-04-0194n/an/a10.1002/jgh3.70163Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus TremelimumabNaohiro Watanabe0Takashi Kobayashi1Michihiro Iwaki2Asako Nogami3Naohiro Wada4Ayako Shimizu5Tomoya Komori6Hirofumi Koike7Yukiko Sahashi8Atsushi Nakajima9Masato Yoneda10Department of Pharmacy Yokohama City University Hospital Kanazawa Ward JapanDepartment of Gastroenterology and Hepatology Yokohama City University Hospital Kanazawa Ward JapanDepartment of Gastroenterology and Hepatology Yokohama City University Hospital Kanazawa Ward JapanDepartment of Gastroenterology and Hepatology Yokohama City University Hospital Kanazawa Ward JapanDepartment of Gastroenterology and Hepatology Yokohama City University Hospital Kanazawa Ward JapanDepartment of Pharmacy Yokohama City University Hospital Kanazawa Ward JapanDepartment of Pharmacy Yokohama City University Hospital Kanazawa Ward JapanDepartment of Pharmacy Yokohama City University Hospital Kanazawa Ward JapanDepartment of Pharmacy Yokohama City University Hospital Kanazawa Ward JapanDepartment of Gastroenterology and Hepatology Yokohama City University Hospital Kanazawa Ward JapanDepartment of Gastroenterology and Hepatology Yokohama City University Hospital Kanazawa Ward JapanABSTRACT Aims In March 2024, the American Society of Clinical Oncology recommended the combination of tremelimumab plus durvalumab as a treatment for advanced hepatocellular carcinoma (HCC). Although safety data for first‐line treatments are available, information on adverse events related to late‐line treatments is limited. This study aimed to identify risk factors for adverse events in patients who received this combination. Methods and Results We conducted a retrospective cohort study from March 2023 to January 2025 at Yokohama City University Hospital, involving 24 patients aged 18 years or older with unresectable HCC. All 24 patients experienced at least one adverse event during treatment. Of these, the incidence of treatment‐related adverse events leading to treatment discontinuation after tremelimumab plus durvalumab therapy was 50.0% (12/24). In the discontinuation group, prior atezolizumab plus bevacizumab therapy (66.7% vs. 16.7%, p = 0.036) was more frequent than in the continuation group. Conclusion In patients with unresectable HCC who received tremelimumab plus durvalumab, the risk of treatment‐related adverse events was associated with prior atezolizumab plus bevacizumab therapy. These factors may increase the likelihood of developing treatment‐related adverse events.https://doi.org/10.1002/jgh3.70163durvalumabimmune checkpoint inhibitorstreatment‐related adverse eventstremelimumabunresectable hepatocellular carcinoma |
| spellingShingle | Naohiro Watanabe Takashi Kobayashi Michihiro Iwaki Asako Nogami Naohiro Wada Ayako Shimizu Tomoya Komori Hirofumi Koike Yukiko Sahashi Atsushi Nakajima Masato Yoneda Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab JGH Open durvalumab immune checkpoint inhibitors treatment‐related adverse events tremelimumab unresectable hepatocellular carcinoma |
| title | Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab |
| title_full | Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab |
| title_fullStr | Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab |
| title_full_unstemmed | Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab |
| title_short | Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment‐Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab |
| title_sort | prior immune checkpoint inhibitor treatment is a risk factor for treatment related adverse events in unresectable hepatocellular carcinoma treated with durvalumab plus tremelimumab |
| topic | durvalumab immune checkpoint inhibitors treatment‐related adverse events tremelimumab unresectable hepatocellular carcinoma |
| url | https://doi.org/10.1002/jgh3.70163 |
| work_keys_str_mv | AT naohirowatanabe priorimmunecheckpointinhibitortreatmentisariskfactorfortreatmentrelatedadverseeventsinunresectablehepatocellularcarcinomatreatedwithdurvalumabplustremelimumab AT takashikobayashi priorimmunecheckpointinhibitortreatmentisariskfactorfortreatmentrelatedadverseeventsinunresectablehepatocellularcarcinomatreatedwithdurvalumabplustremelimumab AT michihiroiwaki priorimmunecheckpointinhibitortreatmentisariskfactorfortreatmentrelatedadverseeventsinunresectablehepatocellularcarcinomatreatedwithdurvalumabplustremelimumab AT asakonogami priorimmunecheckpointinhibitortreatmentisariskfactorfortreatmentrelatedadverseeventsinunresectablehepatocellularcarcinomatreatedwithdurvalumabplustremelimumab AT naohirowada priorimmunecheckpointinhibitortreatmentisariskfactorfortreatmentrelatedadverseeventsinunresectablehepatocellularcarcinomatreatedwithdurvalumabplustremelimumab AT ayakoshimizu priorimmunecheckpointinhibitortreatmentisariskfactorfortreatmentrelatedadverseeventsinunresectablehepatocellularcarcinomatreatedwithdurvalumabplustremelimumab AT tomoyakomori priorimmunecheckpointinhibitortreatmentisariskfactorfortreatmentrelatedadverseeventsinunresectablehepatocellularcarcinomatreatedwithdurvalumabplustremelimumab AT hirofumikoike priorimmunecheckpointinhibitortreatmentisariskfactorfortreatmentrelatedadverseeventsinunresectablehepatocellularcarcinomatreatedwithdurvalumabplustremelimumab AT yukikosahashi priorimmunecheckpointinhibitortreatmentisariskfactorfortreatmentrelatedadverseeventsinunresectablehepatocellularcarcinomatreatedwithdurvalumabplustremelimumab AT atsushinakajima priorimmunecheckpointinhibitortreatmentisariskfactorfortreatmentrelatedadverseeventsinunresectablehepatocellularcarcinomatreatedwithdurvalumabplustremelimumab AT masatoyoneda priorimmunecheckpointinhibitortreatmentisariskfactorfortreatmentrelatedadverseeventsinunresectablehepatocellularcarcinomatreatedwithdurvalumabplustremelimumab |